Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $62.25 Average PT from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given a consensus rating of “Moderate Buy” by the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $62.25.

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Citigroup assumed coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 price target for the company. Finally, Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th.

Insiders Place Their Bets

In other Celldex Therapeutics news, CEO Anthony S. Marucci bought 11,500 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were bought at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 3.80% of the company’s stock.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Teachers Retirement System of The State of Kentucky grew its holdings in Celldex Therapeutics by 5.1% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock worth $1,449,000 after buying an additional 2,070 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Celldex Therapeutics by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock worth $52,372,000 after acquiring an additional 6,557 shares in the last quarter. Barclays PLC raised its holdings in shares of Celldex Therapeutics by 140.7% in the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company’s stock valued at $4,431,000 after purchasing an additional 76,207 shares during the last quarter. Y Intercept Hong Kong Ltd raised its holdings in shares of Celldex Therapeutics by 11.5% in the third quarter. Y Intercept Hong Kong Ltd now owns 30,538 shares of the biopharmaceutical company’s stock valued at $1,038,000 after purchasing an additional 3,146 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Celldex Therapeutics during the third quarter valued at about $1,561,000.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX opened at $25.12 on Friday. The firm has a 50 day moving average price of $26.31 and a two-hundred day moving average price of $32.93. The stock has a market cap of $1.67 billion, a P/E ratio of -9.77 and a beta of 1.57. Celldex Therapeutics has a 52-week low of $22.93 and a 52-week high of $53.18.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.